Corsera Health has raised US$80m in Series A funding to develop preventive RNAi medicines and AI tools to predict and prevent cardiovascular disease.
The Boston-based company has begun dosing patients in a Phase 1 clinical trial of COR-1004, a drug designed to lower cholesterol by silencing PCSK9, a gene that regulates LDL cholesterol in the blood.
Corsera is developing medicines using RNA interference (RNAi), which silences specific genes to reduce disease-causing proteins.
Its approach targets elevated LDL cholesterol and high blood pressure, the two main drivers of atherosclerotic cardiovascular disease, where plaque builds up in artery walls.
The medicines are designed for once-annual administration to enable broad access.
Clive Meanwell, co-founder and co-chief executive of Corsera Health, said: “At Corsera, we are motivated by a bold vision: a world without cardiovascular disease.
“We are making strong progress towards a future in which preventive care enables people to live longer, healthier lives, and the initiation of our first clinical trial marks an important milestone on that journey.”
The Series A round was co-led by Forbion and Population Health Partners.
The company expects initial proof-of-concept data in 2026, with a second Phase 1 trial anticipated to begin in mid-2026.
John Maraganore, co-founder and co-chief executive of Corsera Health, said: “By combining AI-enabled prediction of lifetime ASCVD risk with preventive RNAi medicines, Corsera has the potential to change the trajectory of cardiovascular disease, enabling earlier intervention and broad access to prevention at a population scale.”
